Roth Affirms Cytori Therapeutics (CYTX) at 'Buy' Following Phase III STAR Trial Enrollment Milestone
-
Roth Keeps Cytori Therapeutics (CYTX) at 'Buy' Following Scleradec-I Trial Results; Data Bodes Well for Pivotal Program
-
Roth Capital Cuts Price Target on Cytori Therapeutics (CYTX) Following 2Q Earnings Report
-
Pace of ECCO-50 Development in OA Patients Remains Robust; Roth Affirms Cytori Therapeutics (CYTX) at 'Buy'
-
Cytori Therapeutics (CYTX) Prices Direct Offering at 77c/Unit
-
Cytori Prices Registered Direct Offering Providing for up to $25 million in Equity Financing
-
Roth 'Encouraged' by Cytori Therapeutics' (CYTX) Scleradec-I Study; Sees Mid-2015 Start for STAR Study
-
Streetinsider.com's Hot Lunchtime Reads 4/6: (RAD) (ALTR) (EMN) (NOW) (CYTX)
-
Celution System Clearance in China is 'Major Win' for Cytori (CYTX) - Roth Capital
-
Cytori to Provide Corporate Update at the 27th Annual ROTH Conference in Laguna Niguel, California
-
Roth Positive on Expansion of STAR Study Sites; Afforms Cytori (CYTX) at 'Buy'
-
Roth Still Positive on Cytori (CYTX) as ACT-OA Phase 2 Commences
-
Streetinsider.com's Hot Lunchtime Reads 1/16: (CYTX) (FB) (AAPL) (C) (INTC)
-
Roth Capital Nearly Doubles PT on Cytori (CYTX) to $6; Positive on Phase III STAR for Scleroderma
-
Roth Affirms Cytori Therapeutics (CYTX) at 'Buy'; BARDA Affirms Strong Support for Thermal Burn Cell Therapy
-
Pre-Open Stock Movers 12/10: (SNSS) (RVLT) (COST) Higher; (GDP) (ALLT) (YUM) Lower (more...)
-
Roth Affirms Cytori (CYTX) at 'Buy'; Celution, ADRCs 'de-Risked' in Japan on New Regulatory Measures
-
Roth Capital 'Encouraged' by Cytori (CYTX) Receiving FDA Approval to Continue ATHENA
-
Cytori Therapeutics (CYTX) Closes on $13.5M in Financing
-
Cytori Therapeutics (CYTX) Announces $13.5M Registered Direct Placement
-
Roth Affirms Cytori (CYTX) at Buy Following BARDA Update
-
NHLBI Trial Choice Validates Cytori (CYTX) as Top Stem Cell Player - Roth Capital
-
Roth Capital 'Encouraged' by Notice of Intent in Cytori's (CYTX) Contract with BARDA
-
Roth Keeps Cytori Therapeutics (CYTX) at 'Buy'; Still Encouraged by Streamlining Efforts
-
Roth Capital Starts Cytori Therapeutics, Inc. (CYTX) at Buy
-
Morning Movers 05/10: (ADY) (INSP) (KERX) (CYTX) Higher; (SGI) (CDTI) (ARX) (WFR) Lower
-
Morning Movers 01/08: AEN, CYCC, SPDE, LEI, HTX, LUNA Higher; SNTA, ROG, DMAN, LWSN Lower

